WO2002072128A1 - Cross-linked gelatin composition comprising a wetting agent - Google Patents

Cross-linked gelatin composition comprising a wetting agent Download PDF

Info

Publication number
WO2002072128A1
WO2002072128A1 PCT/US2002/003381 US0203381W WO02072128A1 WO 2002072128 A1 WO2002072128 A1 WO 2002072128A1 US 0203381 W US0203381 W US 0203381W WO 02072128 A1 WO02072128 A1 WO 02072128A1
Authority
WO
WIPO (PCT)
Prior art keywords
gelatin
cross
wetting agent
composition
linked gelatin
Prior art date
Application number
PCT/US2002/003381
Other languages
French (fr)
Inventor
Richard J. Greff
Original Assignee
Sub-Q, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sub-Q, Inc. filed Critical Sub-Q, Inc.
Priority to EP02720915.4A priority Critical patent/EP1389125B1/en
Publication of WO2002072128A1 publication Critical patent/WO2002072128A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028Polypeptides; Proteins; Degradation products thereof
    • A61L26/0038Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0085Porous materials, e.g. foams or sponges
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/009Materials resorbable by the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Definitions

  • This invention is directed to a biocompatible, hemostatic cross-linked gelatin composition comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
  • This invention is further directed towards methods of decreasing the hydration time of cross-linked gelatin by incorporating a biocompatible wetting agent into the gelatin.
  • This invention further relates to a kit of parts for preparing a biocompatible, hemostatic cross-linked gelatin composition comprising a sterile syringe and non-hydrated, biocompatible, pledget comprising a cross-linked gelatin and a wetting agent.
  • Cross-linked gelatin often in the form of gelatin foam, gelatin film or gelatin sponges, has been used as a hemostatic agent since its development by Correll in 1945.
  • hemostatic sponges or foams are used routinely to pack wounds, absorb blood and stop bleeding. They are often left in place to be bioabsorbed over a period of weeks to months.
  • medicaments such as antibiotics, growth factors and thrombus enhancing agents, have been incorporated into the cross-linked gelatin to enhance the in vivo properties of the composition.
  • the hemostatic sponge is placed onto or into the wound, whereupon it absorbs blood or other fluids, expands to pack and compress the wound, and initiates a rapid clotting response.
  • the sponge must first be pre-hydrated or wetted, usually with sterile saline, before placement in the wound.
  • This pre-hydration step often accompanied with gentle compression and/or massaging of the sponge, can be time consuming and troublesome, often yielding non-uniform results at a critical moment in patient care.
  • the hydrated sponge can then be compressed by hand and inserted or tamped into the wound.
  • One particular wound suitable for use by hydrated sponges is a puncture site such as a puncture wound resulting from catheter insertion or a biopsy needle. When so used, the art describes ejection of a pledget of cross-linked gelatin from a syringe into the puncture site. 8"10
  • Critical to the ejection process is the flowability of the pledget from the syringe assembly and retention of its structural integrity during insertion into the body.
  • ejection of the pledget from the syringe assembly is preferably conducted with, at most, moderate pressure to ensure accurate placement in vivo.
  • Efficient ejection of the pledget in turn, relates to the flowability of the cross- linked gelatin through the syringe assembly.
  • Higher fluid content pledgets are believed to correlate with enhanced flowability and, accordingly, it is desirable to maintain as high a fluid absorbability content in the sterilized pledget as possible.
  • the structural integrity of the pledget is substantially maintained as it is ejected from the syringe assembly when placed in vivo in order to ensure that portions of the pledget are not torn or otherwise separated from the pledget.
  • This criticality is particularly important when the pledget is placed over a blood vessel puncture in order to avoid unintended thrombosis of the vessel.
  • Structural integrity of the gelatin composition of the pledget under pressure is believed to correlate with the tensile strength of the composition and, accordingly, it is desirable to maintain as high a tensile strength in the sterilized pledget as possible.
  • This invention is directed to a biocompatible, hemostatic, cross-linked gelatin composition which has a wetting agent incorporated therein.
  • this invention is directed to a biocompatible material comprising a cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
  • This invention further relates to methods of using this composition to decrease the hydration time of a hemostatic, cross-linked gelatin composition.
  • This invention further relates to a kit of parts for preparing a biocompatible, hemostatic, cross-linked gelatin composition comprising a sterile syringe and non-hydrated, biocompatible, pledget comprising a cross-linked gelatin and a wetting agent.
  • wetting agents can be incorporated into a cross-linked gelatin composition, improving their use as, e.g., a hemostatic sponge.
  • Applicants have further surprisingly found that the incorporation of wetting agents into a hemostatic, cross-linked gelatin composition decreases the hydration time needed to prepare the gelatin for use. Incorporation of the wetting agent into the cross-linked gelatin composition provides for one or more of improved fluid absorption, gelatin expansion and wound compression.
  • hemostatic, cross-linked gelatin compositions with wetting agents incorporated therein are more uniformly lubricated when ejected as a pledget from a syringe assembly and less likely to suffer damage to the structural integrity of the pledget.
  • Such pledgets are also more quickly hydrated, allowing for hydration of the pledget inside the injection syringe.
  • the pledgets made according to the invention are more uniformly hydrated, and less likely to become distorted during the hydration process.
  • this invention is directed to a biocompatible, hemostatic, cross-linked gelatin composition
  • a biocompatible, hemostatic, cross-linked gelatin composition comprising a cross- linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
  • the incorporation of the wetting agent into the cross- linked gelatin can be achieved by mixing or impregnating the gelatin with wetting agent prior to foaming.
  • the wetting agent can comprise from about 0.01 to 10 weight percent of the gelatin and preferably from about 0.1 to 10 weight percent.
  • the incorporation of the wetting agent into the cross-linked gelatin can be achieved by coating the wetting agent over the surface of a gelatin sponge.
  • a solution of wetting agent and liquid solvent carrier is prepared wherein the wetting agent comprises from about 0.01 to 20 percent of the solution and preferably from about 1 to 10 weight percent.
  • the solution is coated over the surface of the sponge, then the liquid solvent carrier is evaporated.
  • the wetting agent comprises from about 0.01 to about 5 weight percent of the gelatin sponge and preferably from about 0.1 to about 5 weight percent.
  • the biocompatible, hemostatic sponge can be bioabsorbable.
  • the sponge can also include one or more compositions selected from the group consisting of growth factors, thrombus enhancing agents, and antimicrobial agents.
  • the invention is directed to a method for decreasing the hydration time of a cross-linked gelatin composition which method comprises, prior to hydration of said cross-linked gelatin, incorporating a biocompatible wetting agent with said cross-linked gelatin.
  • the biocompatible, hemostatic sponge of the present invention can be sterilized and packaged to facilitate use in surgical procedures.
  • this invention is directed to a kit of parts for preparing a biocompatible, hemostatic, cross-linked gelatin composition
  • a biocompatible, hemostatic, cross-linked gelatin composition comprising a syringe or syringe assembly and a non-hydrated pledget, said pledget comprising a cross-linked gelatin and wetting agent.
  • This invention is directed to a biocompatible, hemostatic, cross-linked gelatin composition which has a wetting agent incorporated therein.
  • this invention is directed to a biocompatible material comprising a cross-linked gelatin and a sufficient amount of wetting agent incorporated therein to permit uniform wetting of the sponge in the presence of an aqueous solution and to methods of using this composition to decrease the hydration time of the gelatin composition.
  • cross-linked gelatin refers to well known gelatin foams or sponges which are cross-linked with a conventional cross-linking agent such as formaldehyde as described in the art by Correll. 1"3
  • cross-linked gelatin composition refers to compositions comprising cross-linked gelatin. Such compositions often include other components such as a medicament 8"10 or a second polymer such as collagen 13 and starch 6 .
  • growth factors refers to those medicaments which are conventionally employed to facilitate tissue growth such as the endothelial wall of a punctured blood vessel or biopsy tract.
  • suitable growth factors include PDGF, EGF, FGF, IGF's 1 and 2, TGF and the like.
  • thrombus enhancing agents refers to those medicaments which are conventionally employed to facilitate thrombus formation at a puncture site such as at the endothelial wall of a punctured blood vessel or a biopsy tract.
  • suitable thrombus enhancing agents include thrombin, fibrinogen, Factor XIII and other coagulation factors.
  • antimicrobial agent refers to agents which destroy microbes (i.e., bacteria, fungi, viruses and microbial spores) thereby preventing their development and pathogenic action.
  • Preferred antimicrobial agents include antibiotics and antiviral agents and, in particular, antibiotics.
  • Other preferred antimicrobials include, for example, iodine containing materials such as PNP-I 2 , chlorhexidene, and the like.
  • packaging element refers to those packaging components used to encase the cross-linked gelatin and include, by way of example, boxes, syringes, envelopes, tubings, catheters, introducers and the like.
  • the packaging elements may comprise glass, plastic, ceramics, cardboard, paper products and the like.
  • wetting agent refers to a biocompatible agent which facilitates or enhances the hydration or lubrication of a hemostatic sponge.
  • suitable wetting agents include polyoxyalkylenes (such as BASF Pluronics, UCC Carbowaxes, PEGs), ether capped polyoxyalkylenes, e.g., polyoxyethylene lauryl ether, ester capped polyoxyalkylenes, e.g., polyoxyethylene stearate, sorbitan esters (such as certain products called Span and Tween), phosphatides (such as lecithin), alkyl amines, glycerin, water soluble polymers such as polyethylene oxides, carboxy methyl cellulose, poly vinyl alcohol, and polyvinyl pyrrolidone, surfactants such as alkyl (C 6 -C 20 ) sulfate salts, e.g., sodium lauryl sulfate, aryl (C 6 -C 10 ) s
  • compositions of this invention include biocompatible hemostatic, cross- linked gelatin compositions comprising a cross-linked gelatin composition and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
  • the wetting agent is utilized in an amount sufficient to enhance the hydration and/or lubrication of the composition.
  • the wetting agent When the wetting agent is incorporated into the cross-linked gelatin, the wetting agent will comprise from about 0.01 to about 10 weight percent based on the total weight of the composition and preferably from about 0.1 to 10 weight percent.
  • the wetting agent When the wetting agent is coated onto the surface of the cross-linked gelatin, the wetting agent will comprise from about 0.01 to about 20 weight percent, based on the total weight of the applied solution (preferably from about 1 to 20 weight percent), and 0.01 to 5 weight percent based on the total weight of the gelatin composition after evaporation of the liquid solvent of the applied solution (and preferably from about 0.1 to 5 weight percent).
  • the cross-linked gelatin composition further comprises a medicament such as an antimicrobial agent (e.g., an antibiotic), growth factors, thrombus enhancing agents, and the like or a property modifying agent such as a wetting agent.
  • a medicament such as an antimicrobial agent (e.g., an antibiotic), growth factors, thrombus enhancing agents, and the like or a property modifying agent such as a wetting agent.
  • an antimicrobial agent e.g., an antibiotic
  • growth factors e.g., thrombus enhancing agents
  • a property modifying agent such as a wetting agent.
  • Suitable medicaments can be mixed with or impregnated into the cross-linked gelatin composition prior to sterilization procedures.
  • the medicament is utilized in an amount sufficient for its intended purpose, e.g., an antimicrobially effective amount, an amount sufficient to induce thrombus formation, and an amount sufficient to promote growth.
  • the specific amount employed relates to the effectiveness of the medicament, the disease condition of the patient being treated, the age and weight of the patient, the location of the disease and other factors well within the purview of the attending clinician.
  • the gelatin Prior to administration of the biocompatible, hemostatic, cross-linked gelatin to the patient, the gelatin will be sterilized. Sterilization can be achieved by, for example, heat or E-beam sterilization. Biocompatible wetting agents will typically be incorporated into or coated onto the cross-linked gelatin composition prior to the sterilization procedure. E-beam sterilization of a cross-linked gelatin composition is described in U.S. Provisional Patent Application Serial No.
  • a pledget of the cross-linked gelatin composition of the present invention can be inserted into a syringe assembly comprising a holding chamber, an injection port which comprises a luer hub, and an ejection port which is attached to a cannula.
  • the syringe assembly containing the pledget can packaged and sterilized.
  • sterile saline can be added to the holding chamber in a sufficient amount to hydrate the pledget. Once the pledget is hydrated, the pledget can be transferred into the cannula attached to the ejection port.
  • the incorporation of wetting agents into the cross-linked gelatin composition can allow for rapid, uniform wetting of the gelatin and elimination of the pre-hydration process.
  • the wetting agent can be added and dissolved (or dispersed) directly into the hemostat chemical formulation, preferably just before the foaming process.
  • An amount of wetting agent ranging from about 0.01 to 10 percent based on the weight of the gelatin material, and preferably from 0.1 to 10 percent, can be used. Processes for manufacturing a hemostatic sponge are disclosed in U.S. Patent No. 2,465,357 3 and U.S. Patent No. 2,507,244 4 .
  • the wetting agent could be dissolved (or dispersed) in a non- aqueous liquid solvent (e.g., ethanol, isopropanol, acetone and the like) coated onto the cross-linked gelatin composition and the liquid solvent removed by evaporation.
  • a non- aqueous liquid solvent e.g., ethanol, isopropanol, acetone and the like
  • the wetting agent and liquid solvent mixture could be applied onto the gelatin composition and the foam compressed. The liquid solvent would then be removed by evaporation.
  • the concentration of the wetting agent in the liquid solvent is preferably from about 0.01 to 20 percent and preferably from 1 to 20 weight percent and more preferably 1 to 10 weight percent.
  • Suitable biocompatible wetting agents are commercially available and include, for example, sodium lauryl sulfate, Pluronic F-68, Pluronic F-38, Pluronic P-105, Pluronic- 10R5, Tween 20, Tween 60, Tween 85, Brij 35, Brij 78, Myrj 52, PEG 600, glycerin and the like.
  • biocompatible wetting agents can be incorporated into biocompatible collagen hemostatic sponges (e.g., ActifoamTM) to improve their wetting times in the manner and concentrations set forth above.
  • Suitable wetting agents include Tween 20 (1 % in isopropanol) and Pluronic P- 105(1 % in isopropanol).
  • RO water reversed osmosis water
  • the purpose of this example is to demonstrate the feasibility of different agents in reducing the hydration time of a cross-linked gelatin having a variety of candidate wetting agents incorporated into the gelatin prior to foaming (Gelatin Composition 1A).
  • the surfactant was added to the solution used to prepare the cross-linked gelatin foam.
  • Gelatin Composition 1A was prepared as follows. A stock solution of 5% pigskin gelatin in purified bottled water was prepared by heating to 60 °C with constant stirring. The solution was cooled to 37°C and 0.01 % formalin added. This was incubated for two hours. To produce a 10% surfactant to gelatin ratio (i.e., 10% loading), 1.5 grams of surfactant was dissolved in 20 grams of water, and this solution added to 280 gram aliquots of the stock gelatin solution. Foam was produced by whipping air into the warm mixture for about 2 minutes using a kitchen blender. The whipping ceased when the foam peaked. The gelatin foam was then transferred to screens and contained within metal shells until firm, about 10 - 15 minutes.
  • Pluronic F-68 poly(ethylene oxide)-co-(propylene oxide) block
  • a non-iomc wetting agent number average molecular weight of about 8400
  • Tween 20 polyoxyethylene sorbitan monolaurate
  • Tween 20 as a sample of a non-ionic wetting agent - molecular weight of approximately 1227
  • Comparative Gelatin Composition IB was prepared as above except for omission of the wetting agent.
  • gelatin compositions 1A produced with lauryl sulfate, Pluronic F-68,
  • Tween 20 and 30% lauryl sulfate candidate wetting agents were softer and less compressible. These compositions also displayed some loss of foam height and an increase in cell size and voids. The Tween 20 and 30% lauryl sulfate formulations demonstrated the most collapse and increase in cell size and voids.
  • Table 1 sets forth the hydration times for the Gelatin Compositions 1A and the Comparative Gelatin Compositions. Hydration was tested in both uncompressed and compressed (comp.) foams. The concentration of candidate wetting agent in each composition is indicated as a percent loading. Specifically, the percent loading refers to the weight percent of the wetting agent based on gelatin in the composition before foaming based on a 300 mL solution containing 5% gelatin.
  • the Gelatin Compositions 1A with the lauryl sulfate (30% loading), Tween 20 and Pluromc F-68 wetting agents yielded a startling reduction in hydration time of about 3 to 10 seconds (versus 6 minutes for the Comparative Gelatin
  • Composition IB (control) The amount of water absorbed was somewhat reduced for the 30% lauryl sulfate containing sample. It was basically unchanged for the other two compositions. Unless otherwise noted, all samples were the aggregate of 3 pieces.
  • the wet/dry ratio reported is the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material.
  • the above data indicates that all of the candidates used, with the exception of polyacrylamide, act as wetting agents per this invention.
  • the increase in wetting time provided by using polyacrylamide indicates that this material is not a suitable wetting agent.
  • the above data of the different agents used little or no change in the wet/dry ratio occurred with the use of either Tween 20 or PEG 600; modest lowering of the wet/dry ratio occurred with the use of Pluronic F-68 and Glycerin; and somewhat greater lowering of the wet/dry ratio occurred with the use of lauryl sulfate.
  • the purpose of this example is to demonstrate the reduction in hydration time of a cross-linked gelatin composition containing different non-ionic wetting agents (Gelatin Composition 2A) and forming a surfactant coating on the preformed cross-linked gelatin foam composition.
  • the wetting agents were coated onto the cross-linked gelatin composition in the following manner: the wetting agent was added to a solvent, the cross-linked gelatin composition was added to the resulting solution, the soak time used was 10 seconds or 1 minute, as indicated below, the cross-linked gelatin composition was removed, excess liquid drained, and then the solvent was allowed to evaporate.
  • Gelatin Composition 2 A was prepared as follows. First, Comparative Gelatin Composition IB, as set forth in Example 1, was prepared. Second, ten percent solutions of each of the following wetting agents were prepared in isopropanol (2-Propanol, ACS reagent (Aldrich Cat. #19076-4)) in 30 cc screw cap vials.
  • Tween 20 polyoxyethylene (20) sorbitan monolaurate
  • Tween 60 polyoxyethylene (20) sorbitan monostearate) (Aldrich Cat. #37425-3)
  • Tween 85 polyoxyethylene (20) sorbitan trioleate
  • Brij 35 polyoxyethylene (23) lauryl ether
  • Myrj 52 polyoxyethylene (40) stearate) (Aldrich Cat. #P3440) (BASF)
  • a 2 x 2 x 0.6 cm piece of Gelatin Composition 2 A was placed into each vial and the vial inverted to soak the composition with the solution. This was repeated for each solution. Two contact/soak times were employed, 10 seconds and one minute. The coated Gelatin Compositions 2A were then removed, drained of excess liquid and air dried overnight.
  • Comparative Gelatin Composition 2B (untreated) was prepared as set forth for Comparative Gelatin Composition IB in Example 1.
  • Comparative Gelatin Composition 2C carrier solvent coating
  • a 2 x 2 x 0.6 cm piece of Comparative Gelatin Composition IB (as set forth in Example 1) was placed into a 30 cc screw cap vial of isopropanol and the vial inverted to soak the composition with the solution. Two contact/soak times were employed, 10 seconds and one minute. After soaking, the gelatin compositions were then air dried overnight.
  • the wet/dry ratio reported is the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material. All samples of cross-linked gelatin, treated or not, yielded very large and similar uptakes for water (wet/dry weight). Also, as evident above, the best wetting agents were deemed those that produced the most rapid hydration, e.g., Tween 20, Brij 35 and Brij 78. EXAMPLE 3
  • the purpose of this example is to demonstrate that the improved hydration time achieved for cross-linked gelatins coated with non-aqueous wetting agents as per Example 2 above were independent of the solvent used to coat the gelatin.
  • gelatin composition 3 A was prepared in the same manner as gelatin composition 2A.
  • the wetting agent coating solution comprises a selected wetting agent and a carrier solvent of either ethanol or isopropanol. Soak contact time of the foam in the wetting solution was about 10 seconds each.
  • the gelatin compositions were compressed and soaked in a 250 mL beaker containing 100 mL of RO water. The hydration times were measured as in Example 2.
  • the specific wetting agents employed were as follows:
  • Tween 20 polyoxyethylene (20) sorbitan monolaurate
  • Pluronic F-68 poly(ethylene oxide)-co-(propylene oxide) block
  • a non-ionic wetting agent average molecular weight of about 8400
  • Pluronic P-105 poly(ethylene oxide)-co-(propylene oxide) polymer
  • Pluronic P-105 (poly(ethylene oxide)-co-(propylene oxide) polymer), (as a sample of a non- ionic wetting agent- average molecular weight of about 6500) (commercially available from BASF Corp.)
  • Pluronic- 10R5 poly(ethylene oxide)-co-(propylene oxide) polymer
  • Pluronic-F38 poly(ethylene oxide)-co-(propylene oxide) block
  • Pluronic wetting agent— average molecular weight of about 5000 commercially available from BASF Corp.
  • the average wet/dry ratio for the above samples was approximately 44 with a range of from 39-56 wherein this ratio is calculated by the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material.
  • the solvent employed should be non-aqueous to the extent that water irreversible damages the foam.
  • the non-aqueous solvent is ethanol and/or isopropanol since methanol causes some degradation of the foam properties and acetone exhibits a disagreeable odor.
  • This example examines the effect of wetting agent concentration on hydration time used to coat the cross-linked gelatin composition.
  • cross-linked gelatin compositions with wetting agent coatings were prepared as in Example 2.
  • the wetting agent coating solutions were prepared with concentrations of the selected wetting agents of 0.1, 1.0, 3.0 and 10.0% .
  • the hydration times were measured on compressed samples, in the manner set forth in Example 2. All of the wetting agents and concentrations demonstrated rapid hydration times, although at the highest concentration of 10%, the hydration time was somewhat reduced.
  • Table 4 below. Where multiple values are given, multiple runs were made.
  • the wet/dry ratio reported is the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material.
  • This example evaluates the effect of wetting agent concentration used during the formation of a gelatin foam composition on both the hydration time and the wet/dry ratio.
  • This example differs from the previous example in that the wetting agent is added to the composition prior to foam formation as per Example 1 rather than coating a prior formed cross-linked gelatin foam with the wetting agent as per Examples 2-4.
  • cross-linked gelatin compositions with wetting agents incorporated therein were prepared as in Example 1 except that 0.02 weight percent of formalin was used and wherein the wetting agent was added to the gelatin composition prior to foam formation.
  • the wetting agent coating solutions were prepared with concentrations set forth in Table 5.
  • hydration times for these gelatin compositions were measured by manually compressing each cut sample and dropping it into a beaker containing 150 mL of tap water. Hydration was complete when the foam turned translucent and were measured on compressed samples, in the manner set forth in Example 2. Hydration time of a control, similar to Comparative Gelatin Example 2B, was also measured.
  • wetting agent when the wetting agent is incorporated prior to cross-linked gelatin foam formation, very low concentrations of wetting agent are preferred. Moreover, the data indicates minimal impact of low concentrations of wetting agent on reduced hydration time indicating that such low concentrations advantageously provide for a composition closer to control in many properties but surprisingly have excellent hydration times as compared to control.
  • Preferred wetting agents as demonstrated in this example utilizing the addition of wetting agent prior to foam formation should not prevent foam sponge formation of the cross-linked gelatin.
  • PTT partial thromboplastin test
  • the PTT assay is a general screening assay for the detection of coagulation abnormalities in the intrinsic coagulation pathway. This is particularly important because, notwithstanding improved hydration time, a cross- linked gelatin composition having an adverse effect on blood clotting would be contra-indicated for use, e.g., as a hemostatic sponge. Specifically, in this example, fresh whole human blood was drawn at
  • compositions of this invention exhibit substantially equivalent effects on clotting time as compared to control and, accordingly, it was concluded that these compositions are compatible for use as, e.g., hemostatic sponges.
  • EXAMPLE 7 This example evaluates the histopathologic results of a total of 2 arterial femoral puncture sites from one pig, using the compositions of this invention. The objective of this evaluation was to assess the acute and chronic outcome of femoral puncture sites following closure with the compositions of this invention delivered into the tissue tract adjacent to the vessel puncture using a cannula delivery tube.
  • the puncture wound in the right femoral artery was sealed with cross-linked gelatin composition comprising 0.1 % Tween 20 obtained from solvent coating of the composition per Example 2 above.
  • the puncture wound in the left femoral artery was sealed with cross-linked gelatin composition comprising 0.3% Tween 20 obtained from solvent coating of the composition per Example 2 above. Subsequently, approximately 2-4 weeks later, the animal was sacrificed, the arteries adjacent the femoral puncture site were excised and fixed in formalin.
  • the formalin-fixed arterial explants were trimmed in the area of interest every 3 mm into 11 to 14 segments (sections 1 to 14).
  • the sections' sequence was started at the proximal end of each explant.
  • the sections were embedded in paraffin, sectioned at approximately 5 microns three times serially, and stained with Hematoxylin and Eosin (HE), Masson's Trichrome (MT), and Verhoeffs Van Gieson (VVG) stain, respectively. Histologic evaluation was performed and data were recorded.
  • HE Hematoxylin and Eosin
  • MT Masson's Trichrome
  • VVG Verhoeffs Van Gieson
  • a 1 to 5 grading scale was utilized, where 1 is minimal, 2 is mild, 3 is moderate, 4 is marked, and 5 is severe.
  • Loss of endothelium was graded according to circumferential spread of the change. The change of endothelium loss spanned approximately up to 20% of the circumference in grade 1, 20-40% in grade 2, 40-60% in grade 3, 60-80% in grade 4 and more than 80% in grade 5.
  • Necrosis of the media was graded according to depth extension. The change of media necrosis extended into approximately up to 20% of the media thickness in grade 1, 20-40% in grade 2, 40-60% in grade 3, 60-80% in grade 4 and more than 80% in grade 5.
  • Transmural laceration (puncture site) was observed in section 8 (18-21 mm, recut 3) and was characterized by bifocal laceration across the vessel with proliferation of fibrous granulation tissue across the lumen dividing the pre-existing arterial wall into two symmetrically placed remnants. The residual lumen was confined to one of the arterial remnants. The lumen was constructed (moderate stensosis) by intimal fibrous proliferation at the puncture site. There was mineralization of the external elastic lamina adjacent to the laceration site. There was moderate fibrosis in the adventitia at the laceration site and in a separate area in the more distant adventitial tissue that most likely corresponds to the puncture tract. There was no residual implant material and there was no significant inflammatory response in the tract. There was minimal to mild loss of endothelium that was considered to be the result of erosion associated with termination catheterization.
  • the access tract produced by the catheter was found in the vascular wall in both samples as a localized fibrosis in the adventitia and focal transmural fibrosis.
  • the left artery displayed bifocal transmural laceration and healing by fibrous connective tissue and media regeneration bridging across the lumen, indicating focal puncture through opposite sides of the vessel.
  • the right artery there was sub-occlusive thrombosis that proceeded from the puncture site and extended proximally.
  • compositions of this invention are well tolerated in vivo.
  • EXAMPLE 8 This example evaluates the cytotoxicity of the compositions of this invention as compared to prior art compositions, i.e., in the absence of a wetting agent.
  • samples were tested in the ISO agarose overlay cytotoxicity test — a test well known in the art for determining cytotoxicity potential. Specifically, samples were placed onto petri dishes, in triplicate, containing agarose the surface of which contains a monolayer of L-929 mouse fibroblast cells which are sensitive to cytotoxic agents. Subsequently, the samples were evaluated for reactivity and grade depending upon the amount of cellular damage or death directly beneath and/or surrounding the material. The scoring is based on the following:
  • zone limited to area under sample 3 zone extends 0.5 to 1.0 cm beyond sample
  • compositions of this invention as ested in this example, are non-cy to toxic.

Abstract

Disclosed is a biocompatible, hemostatic, cross-linked gelatin composition comprising a biocompatible material comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the sponge in the presence of an aqueous solution.

Description

CROSS-LINKED GELATIN COMPOSITION COMPRISING A WETTING AGENT
BACKGROUND OF INVENTION
Field of the Invention
This invention is directed to a biocompatible, hemostatic cross-linked gelatin composition comprising cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution. This invention is further directed towards methods of decreasing the hydration time of cross-linked gelatin by incorporating a biocompatible wetting agent into the gelatin. This invention further relates to a kit of parts for preparing a biocompatible, hemostatic cross-linked gelatin composition comprising a sterile syringe and non-hydrated, biocompatible, pledget comprising a cross-linked gelatin and a wetting agent.
References
The following patent applications and patents are cited and/or referenced in this application as superscript numbers:
' Correll, et al., Proc. Soc. Exp. Biol. N.Y., 58:233 (1945).
2 Correll, et al., Surg. Gyn. and Obst., 82:585 (1945).
3 Correll, et al., U.S. Patent No. 2,465,357, Therapeutic Sponge and Method of Making, issued March 29, 1949. Correll, et al., U.S. Patent No. 2,507,244, Surgical Gelatin Dusting Powder and Process for Preparing Same, issued May 9, 1950.
Studer, et al., U.S. Patent No. 2,558,395, Undenatured Gelatin Hemostatic Sponge Containing Thrombin, issued
June 26, 1951.
Sieger, et al., U.S. Patent No. 2,899,362, Hemostatic Sponges and Method of Preparing Same, issued August 11, 1959.
Song, et al., U.S. Patent No. 5,399,361, Collagen-containing
Sponges as Drug Delivery Compositions for Proteins, issued March 21 1995.
Cragg, et al., U.S. Patent No. 6,071,301, Device and Method for Facilitating Hemostasis of a Biopsy Tract, issued June 6, 2000.
Cragg, et al., U.S. Patent No. 6,086,607, Device and Method for Facilitating Hemostasis of a Biopsy Tract, issued July 11, 2000.
Cragg, et al. , U.S. Patent No. 6, 162, 192, System and Method or Facilitating Hemostasis of Blood Vessel Punctures with
Absorbable Sponge, issued December 19, 2000.
Pawelchak, et al., U.S. Patent No. 4,292,972, Lyophilized Hydrocolloid Foam, issued October 6, 1981.
Sawyer, U.S. Patent No. 4,238,480, Method for Preparing an Improved Hemostatic Agent and Method of Employing the
Same, issued December 9, 1980. 13 Sawyer, U.S. Patent No. 4,404,970, Hemostatic Article and
Method for Preparing and Employing the Same, issued September 20, 1983.
All of the above references are herein incorporated by reference in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference in its entirety.
State of the Art
Cross-linked gelatin, often in the form of gelatin foam, gelatin film or gelatin sponges, has been used as a hemostatic agent since its development by Correll in 1945. Such hemostatic sponges or foams are used routinely to pack wounds, absorb blood and stop bleeding. They are often left in place to be bioabsorbed over a period of weeks to months. In addition, medicaments, such as antibiotics, growth factors and thrombus enhancing agents, have been incorporated into the cross-linked gelatin to enhance the in vivo properties of the composition.5"7 To use, the hemostatic sponge is placed onto or into the wound, whereupon it absorbs blood or other fluids, expands to pack and compress the wound, and initiates a rapid clotting response. However, to achieve complete fluid absorption, rapid expansion, effective wound compression, and vigorous clotting action, the sponge must first be pre-hydrated or wetted, usually with sterile saline, before placement in the wound. This pre-hydration step, often accompanied with gentle compression and/or massaging of the sponge, can be time consuming and troublesome, often yielding non-uniform results at a critical moment in patient care. (See, for example, Directions for Use provided with Gelfoam® - available from Pharmacia Upjohn). The hydrated sponge can then be compressed by hand and inserted or tamped into the wound. One particular wound suitable for use by hydrated sponges is a puncture site such as a puncture wound resulting from catheter insertion or a biopsy needle. When so used, the art describes ejection of a pledget of cross-linked gelatin from a syringe into the puncture site.8"10
Critical to the ejection process is the flowability of the pledget from the syringe assembly and retention of its structural integrity during insertion into the body. Specifically, ejection of the pledget from the syringe assembly is preferably conducted with, at most, moderate pressure to ensure accurate placement in vivo. Efficient ejection of the pledget, in turn, relates to the flowability of the cross- linked gelatin through the syringe assembly. Higher fluid content pledgets are believed to correlate with enhanced flowability and, accordingly, it is desirable to maintain as high a fluid absorbability content in the sterilized pledget as possible. Likewise, it is critical that the structural integrity of the pledget is substantially maintained as it is ejected from the syringe assembly when placed in vivo in order to ensure that portions of the pledget are not torn or otherwise separated from the pledget. This criticality is particularly important when the pledget is placed over a blood vessel puncture in order to avoid unintended thrombosis of the vessel. Structural integrity of the gelatin composition of the pledget under pressure is believed to correlate with the tensile strength of the composition and, accordingly, it is desirable to maintain as high a tensile strength in the sterilized pledget as possible. In addition, it is desirable to perform hydration of the pledgets in the sterile environment of an injection syringe or syringe assembly by addition of a sterile saline solution to the syringe. Such a hydration process is complicated by the potential of distortions in the pledget due to a lack of uniformity and consistency in the rate of hydration of the pledget. Such distortions could cause unanticipated difficulties in fitting the pledget into the identified wound, e.g., puncture. In addition, the length of time normally needed to hydrate the pledget would typically prohibit such a hydration process. Accordingly, it is desired to obtain a quicker, more uniform hydration of the pledget to ensure predictability of the size and shape of the pledget and to facilitate hydration of the pledget inside the injection syringe.
SUMMARY OF THE INVENTION
This invention is directed to a biocompatible, hemostatic, cross-linked gelatin composition which has a wetting agent incorporated therein. In particular, this invention is directed to a biocompatible material comprising a cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution. This invention further relates to methods of using this composition to decrease the hydration time of a hemostatic, cross-linked gelatin composition. This invention further relates to a kit of parts for preparing a biocompatible, hemostatic, cross-linked gelatin composition comprising a sterile syringe and non-hydrated, biocompatible, pledget comprising a cross-linked gelatin and a wetting agent.
Applicants have surprisingly and unexpectedly found that wetting agents can be incorporated into a cross-linked gelatin composition, improving their use as, e.g., a hemostatic sponge.
Applicants have further surprisingly found that the incorporation of wetting agents into a hemostatic, cross-linked gelatin composition decreases the hydration time needed to prepare the gelatin for use. Incorporation of the wetting agent into the cross-linked gelatin composition provides for one or more of improved fluid absorption, gelatin expansion and wound compression.
Applicants have also surprisingly found that hemostatic, cross-linked gelatin compositions with wetting agents incorporated therein are more uniformly lubricated when ejected as a pledget from a syringe assembly and less likely to suffer damage to the structural integrity of the pledget. Such pledgets are also more quickly hydrated, allowing for hydration of the pledget inside the injection syringe. Further, the pledgets made according to the invention are more uniformly hydrated, and less likely to become distorted during the hydration process.
Accordingly, in one embodiment, this invention is directed to a biocompatible, hemostatic, cross-linked gelatin composition comprising a cross- linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
In one embodiment, the incorporation of the wetting agent into the cross- linked gelatin can be achieved by mixing or impregnating the gelatin with wetting agent prior to foaming. In this embodiment, the wetting agent can comprise from about 0.01 to 10 weight percent of the gelatin and preferably from about 0.1 to 10 weight percent.
In another embodiment, the incorporation of the wetting agent into the cross-linked gelatin can be achieved by coating the wetting agent over the surface of a gelatin sponge. In this embodiment, a solution of wetting agent and liquid solvent carrier is prepared wherein the wetting agent comprises from about 0.01 to 20 percent of the solution and preferably from about 1 to 10 weight percent. The solution is coated over the surface of the sponge, then the liquid solvent carrier is evaporated. After evaporation, the wetting agent comprises from about 0.01 to about 5 weight percent of the gelatin sponge and preferably from about 0.1 to about 5 weight percent.
In both embodiments, the biocompatible, hemostatic sponge can be bioabsorbable. The sponge can also include one or more compositions selected from the group consisting of growth factors, thrombus enhancing agents, and antimicrobial agents. In one of its method aspects, the invention is directed to a method for decreasing the hydration time of a cross-linked gelatin composition which method comprises, prior to hydration of said cross-linked gelatin, incorporating a biocompatible wetting agent with said cross-linked gelatin. The biocompatible, hemostatic sponge of the present invention can be sterilized and packaged to facilitate use in surgical procedures.
Accordingly, in another of its aspects, this invention is directed to a kit of parts for preparing a biocompatible, hemostatic, cross-linked gelatin composition comprising a syringe or syringe assembly and a non-hydrated pledget, said pledget comprising a cross-linked gelatin and wetting agent.
DETAILED DESCRIPTION OF THE INVENTION
This invention is directed to a biocompatible, hemostatic, cross-linked gelatin composition which has a wetting agent incorporated therein. In particular, this invention is directed to a biocompatible material comprising a cross-linked gelatin and a sufficient amount of wetting agent incorporated therein to permit uniform wetting of the sponge in the presence of an aqueous solution and to methods of using this composition to decrease the hydration time of the gelatin composition. Prior to describing this invention in further detail, the following terms will first be defined.
Definitions
As used herein, the following terms have the following meanings: The term "cross-linked gelatin" refers to well known gelatin foams or sponges which are cross-linked with a conventional cross-linking agent such as formaldehyde as described in the art by Correll.1"3 The term "cross-linked gelatin composition" refers to compositions comprising cross-linked gelatin. Such compositions often include other components such as a medicament8"10 or a second polymer such as collagen13 and starch6.
The term "growth factors" refers to those medicaments which are conventionally employed to facilitate tissue growth such as the endothelial wall of a punctured blood vessel or biopsy tract. Examples of suitable growth factors include PDGF, EGF, FGF, IGF's 1 and 2, TGF and the like.
The term "thrombus enhancing agents" refers to those medicaments which are conventionally employed to facilitate thrombus formation at a puncture site such as at the endothelial wall of a punctured blood vessel or a biopsy tract. Examples of suitable thrombus enhancing agents include thrombin, fibrinogen, Factor XIII and other coagulation factors.
The term "antimicrobial agent" refers to agents which destroy microbes (i.e., bacteria, fungi, viruses and microbial spores) thereby preventing their development and pathogenic action. Preferred antimicrobial agents include antibiotics and antiviral agents and, in particular, antibiotics. Other preferred antimicrobials include, for example, iodine containing materials such as PNP-I2, chlorhexidene, and the like.
The term "packaging element" refers to those packaging components used to encase the cross-linked gelatin and include, by way of example, boxes, syringes, envelopes, tubings, catheters, introducers and the like. The packaging elements may comprise glass, plastic, ceramics, cardboard, paper products and the like.
The term "wetting agent" refers to a biocompatible agent which facilitates or enhances the hydration or lubrication of a hemostatic sponge. Examples of suitable wetting agents include polyoxyalkylenes (such as BASF Pluronics, UCC Carbowaxes, PEGs), ether capped polyoxyalkylenes, e.g., polyoxyethylene lauryl ether, ester capped polyoxyalkylenes, e.g., polyoxyethylene stearate, sorbitan esters (such as certain products called Span and Tween), phosphatides (such as lecithin), alkyl amines, glycerin, water soluble polymers such as polyethylene oxides, carboxy methyl cellulose, poly vinyl alcohol, and polyvinyl pyrrolidone, surfactants such as alkyl (C6-C20) sulfate salts, e.g., sodium lauryl sulfate, aryl (C6-C10) sulfate salts, and alkaryl (C7-C24) sulfate salts, and the like.
Compositions
The compositions of this invention include biocompatible hemostatic, cross- linked gelatin compositions comprising a cross-linked gelatin composition and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
The wetting agent is utilized in an amount sufficient to enhance the hydration and/or lubrication of the composition. When the wetting agent is incorporated into the cross-linked gelatin, the wetting agent will comprise from about 0.01 to about 10 weight percent based on the total weight of the composition and preferably from about 0.1 to 10 weight percent. When the wetting agent is coated onto the surface of the cross-linked gelatin, the wetting agent will comprise from about 0.01 to about 20 weight percent, based on the total weight of the applied solution (preferably from about 1 to 20 weight percent), and 0.01 to 5 weight percent based on the total weight of the gelatin composition after evaporation of the liquid solvent of the applied solution (and preferably from about 0.1 to 5 weight percent).
In a preferred embodiment, the cross-linked gelatin composition further comprises a medicament such as an antimicrobial agent (e.g., an antibiotic), growth factors, thrombus enhancing agents, and the like or a property modifying agent such as a wetting agent. Mixtures of medicaments and property modifying agents can also be used. Suitable medicaments can be mixed with or impregnated into the cross-linked gelatin composition prior to sterilization procedures. When employed, the medicament is utilized in an amount sufficient for its intended purpose, e.g., an antimicrobially effective amount, an amount sufficient to induce thrombus formation, and an amount sufficient to promote growth. The specific amount employed relates to the effectiveness of the medicament, the disease condition of the patient being treated, the age and weight of the patient, the location of the disease and other factors well within the purview of the attending clinician. Prior to administration of the biocompatible, hemostatic, cross-linked gelatin to the patient, the gelatin will be sterilized. Sterilization can be achieved by, for example, heat or E-beam sterilization. Biocompatible wetting agents will typically be incorporated into or coated onto the cross-linked gelatin composition prior to the sterilization procedure. E-beam sterilization of a cross-linked gelatin composition is described in U.S. Provisional Patent Application Serial No.
60/275,391, filed March 12, 2001, entitled "Methods for Sterilizing Cross-Linked Gelatin Compositions" (Attorney Docket No. 032005-093), which application is incorporated herein by reference in its entirety. Heat sterilization of a cross-linked gelatin composition is described in U.S. Patent No. 2,465, 357.3 In one embodiment, a pledget of the cross-linked gelatin composition of the present invention can be inserted into a syringe assembly comprising a holding chamber, an injection port which comprises a luer hub, and an ejection port which is attached to a cannula. The syringe assembly containing the pledget can packaged and sterilized. Then, sterile saline can be added to the holding chamber in a sufficient amount to hydrate the pledget. Once the pledget is hydrated, the pledget can be transferred into the cannula attached to the ejection port. The incorporation of wetting agents into the cross-linked gelatin composition can allow for rapid, uniform wetting of the gelatin and elimination of the pre-hydration process. The wetting agent can be added and dissolved (or dispersed) directly into the hemostat chemical formulation, preferably just before the foaming process. An amount of wetting agent ranging from about 0.01 to 10 percent based on the weight of the gelatin material, and preferably from 0.1 to 10 percent, can be used. Processes for manufacturing a hemostatic sponge are disclosed in U.S. Patent No. 2,465,3573 and U.S. Patent No. 2,507,2444.
Alternatively, the wetting agent could be dissolved (or dispersed) in a non- aqueous liquid solvent (e.g., ethanol, isopropanol, acetone and the like) coated onto the cross-linked gelatin composition and the liquid solvent removed by evaporation. In another embodiment, the wetting agent and liquid solvent mixture could be applied onto the gelatin composition and the foam compressed. The liquid solvent would then be removed by evaporation. When the wetting agent is coated over the gelatin composition, the concentration of the wetting agent in the liquid solvent is preferably from about 0.01 to 20 percent and preferably from 1 to 20 weight percent and more preferably 1 to 10 weight percent.
Suitable biocompatible wetting agents are commercially available and include, for example, sodium lauryl sulfate, Pluronic F-68, Pluronic F-38, Pluronic P-105, Pluronic- 10R5, Tween 20, Tween 60, Tween 85, Brij 35, Brij 78, Myrj 52, PEG 600, glycerin and the like.
In addition, biocompatible wetting agents can be incorporated into biocompatible collagen hemostatic sponges (e.g., Actifoam™) to improve their wetting times in the manner and concentrations set forth above. Suitable wetting agents include Tween 20 (1 % in isopropanol) and Pluronic P- 105(1 % in isopropanol).
EXAMPLES
The following examples are set forth to illustrate the claimed invention and are not to be construed as a limitation thereof.
In these examples, unless otherwise indicated, all temperatures are in degrees Centrigrade and all percents are weight percents based on the total weight of the composition. Similarly, the following abbreviations are employed herein and are as defined below. Unless defined, the abbreviations employed have their generally accepted meaning: cc = cubic centimeter cm = centimeter EtOH = ethanol g = gram
IPA - isopropyl alcohol min. = minute mm = millimeter mL = milliliters pcs = pieces
RH = relative humidity
RO water = reversed osmosis water
RPM = rotations per minute sec = seconds wt = weight
EXAMPLE 1
Comparison of Hydration Time of Cross-Linked Gelatin with Wetting Agent Incorporated Therein vs. Cross-Linked Gelatin Without
Wetting Agent
The purpose of this example is to demonstrate the feasibility of different agents in reducing the hydration time of a cross-linked gelatin having a variety of candidate wetting agents incorporated into the gelatin prior to foaming (Gelatin Composition 1A). In this example, the surfactant was added to the solution used to prepare the cross-linked gelatin foam.
The results of the amount of time required to wet the gelatin was compared to the hydration time of a cross-linked gelatin which does not have any candidate wetting agents incorporated therein (Comparative Gelatin Composition IB).
A. Preparation of Gelatin Composition 1A
Gelatin Composition 1A was prepared as follows. A stock solution of 5% pigskin gelatin in purified bottled water was prepared by heating to 60 °C with constant stirring. The solution was cooled to 37°C and 0.01 % formalin added. This was incubated for two hours. To produce a 10% surfactant to gelatin ratio (i.e., 10% loading), 1.5 grams of surfactant was dissolved in 20 grams of water, and this solution added to 280 gram aliquots of the stock gelatin solution. Foam was produced by whipping air into the warm mixture for about 2 minutes using a kitchen blender. The whipping ceased when the foam peaked. The gelatin foam was then transferred to screens and contained within metal shells until firm, about 10 - 15 minutes. The foam was dried at 32.2 °C (90 °F) and 18% RH, which took about 24 - 36 hours. Test samples were prepared by cutting the skin from the dried foam buns and cutting cubes of about 1.5 - 2.0 cm from central locations in the bun. For additional information regarding the preparation of such gelatin compositions, see U.S. Patent Nos. 2,465,357 and 2,507,244. The following candidate wetting agents were each incorporated into the gelatin prior to foaming: 1. Polyacrylamide (weight average molecular weight of about 1500) (as a sample of an cationic wetting agent)
2. Sodium lauryl sulfate (as a sample of a anionic wetting agent)
3. Pluronic F-68 (poly(ethylene oxide)-co-(propylene oxide) block), (as a sample of a non-iomc wetting agent— number average molecular weight of about 8400) (commercially available from BASF Corp.)
4. Tween 20 (polyoxyethylene sorbitan monolaurate), (as a sample of a non-ionic wetting agent - molecular weight of approximately 1227)
5. PEG (600) (polyethylene glycol), (as a sample of a non-iomc wetting agent - molecular weight of about 600) 6. Glycerin (as a sample of a non-ionic wetting agent) B. Preparation of Comparative Gelatin Composition IB
Comparative Gelatin Composition IB was prepared as above except for omission of the wetting agent.
C. Comparison of the Foam Properties and Hydration Time of Cross-Linked Gelatin with Wetting Agent Incorporated Therein vs. Gelatin Without Wetting Agent
(1) Foam Properties Most of the gelatin compositions produced a smooth, white, meringue-like foam, which dried into a high, rigid, compressible bun. Gelatin Compositions 1A produced with lauryl sulfate, Pluronic F-68,
Tween 20 and 30% lauryl sulfate candidate wetting agents were softer and less compressible. These compositions also displayed some loss of foam height and an increase in cell size and voids. The Tween 20 and 30% lauryl sulfate formulations demonstrated the most collapse and increase in cell size and voids. (2) Hydration
Table 1 sets forth the hydration times for the Gelatin Compositions 1A and the Comparative Gelatin Compositions. Hydration was tested in both uncompressed and compressed (comp.) foams. The concentration of candidate wetting agent in each composition is indicated as a percent loading. Specifically, the percent loading refers to the weight percent of the wetting agent based on gelatin in the composition before foaming based on a 300 mL solution containing 5% gelatin.
The Gelatin Compositions 1A with the lauryl sulfate (30% loading), Tween 20 and Pluromc F-68 wetting agents yielded a startling reduction in hydration time of about 3 to 10 seconds (versus 6 minutes for the Comparative Gelatin
Composition IB (control)). The amount of water absorbed was somewhat reduced for the 30% lauryl sulfate containing sample. It was basically unchanged for the other two compositions. Unless otherwise noted, all samples were the aggregate of 3 pieces.
TABLE 1 Hydration Times for Gelatin Compositions 1A and Comparative Gelatin Compositions
Figure imgf000016_0001
Figure imgf000017_0001
The wet/dry ratio reported is the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material. The above data indicates that all of the candidates used, with the exception of polyacrylamide, act as wetting agents per this invention. On the other hand, the increase in wetting time provided by using polyacrylamide indicates that this material is not a suitable wetting agent. The above data of the different agents used, little or no change in the wet/dry ratio occurred with the use of either Tween 20 or PEG 600; modest lowering of the wet/dry ratio occurred with the use of Pluronic F-68 and Glycerin; and somewhat greater lowering of the wet/dry ratio occurred with the use of lauryl sulfate.
EXAMPLE 2
Comparison of Hydration Times Cross-Linked Gelatin Compositions with Wetting Agent Coating vs. Cross-Linked Gelatin Compositions without a Wetting Agent Coating
The purpose of this example is to demonstrate the reduction in hydration time of a cross-linked gelatin composition containing different non-ionic wetting agents (Gelatin Composition 2A) and forming a surfactant coating on the preformed cross-linked gelatin foam composition. Specifically, in this example, the wetting agents were coated onto the cross-linked gelatin composition in the following manner: the wetting agent was added to a solvent, the cross-linked gelatin composition was added to the resulting solution, the soak time used was 10 seconds or 1 minute, as indicated below, the cross-linked gelatin composition was removed, excess liquid drained, and then the solvent was allowed to evaporate.
The hydration time required to wet these compositions was compared to the hydration time of a cross-linked gelatin composition without such a wetting agent coating (Comparative Gelatin Composition 2B (no coating) and Comparative Gelatin Composition 2C (carrier solvent coating)).
A. Preparation of Gelatin Composition 2A
Gelatin Composition 2 A was prepared as follows. First, Comparative Gelatin Composition IB, as set forth in Example 1, was prepared. Second, ten percent solutions of each of the following wetting agents were prepared in isopropanol (2-Propanol, ACS reagent (Aldrich Cat. #19076-4)) in 30 cc screw cap vials.
1. Tween 20 (polyoxyethylene (20) sorbitan monolaurate) (Aldrich Cat. # 27434-8)
2. Tween 60 (polyoxyethylene (20) sorbitan monostearate) (Aldrich Cat. #37425-3)
3. Tween 85 (polyoxyethylene (20) sorbitan trioleate) (Aldrich Cat. #38890-4) 4. Brij 35 (polyoxyethylene (23) lauryl ether) (Aldrich Cat.
#85836-6) (Sigma)
5. Myrj 52 (polyoxyethylene (40) stearate) (Aldrich Cat. #P3440) (BASF)
6. Brij 78 (polyoxyethylene (23) steryl ether) (Sigma #23600-4)
A 2 x 2 x 0.6 cm piece of Gelatin Composition 2 A was placed into each vial and the vial inverted to soak the composition with the solution. This was repeated for each solution. Two contact/soak times were employed, 10 seconds and one minute. The coated Gelatin Compositions 2A were then removed, drained of excess liquid and air dried overnight.
B. Preparation of Comparative Gelatin Composition 2B and 2C
Comparative Gelatin Composition 2B (untreated) was prepared as set forth for Comparative Gelatin Composition IB in Example 1. Comparative Gelatin Composition 2C (carrier solvent coating) was prepared as follows. A 2 x 2 x 0.6 cm piece of Comparative Gelatin Composition IB (as set forth in Example 1) was placed into a 30 cc screw cap vial of isopropanol and the vial inverted to soak the composition with the solution. Two contact/soak times were employed, 10 seconds and one minute. After soaking, the gelatin compositions were then air dried overnight.
C. Comparison of Hydration Times
Dry samples of each of the Gelatin Compositions 2 A and the Comparative Gelatin Compositions 2B and 2C were compressed to about 0.1 cm and dropped into a 250 mL beaker containing 100 mL of RO water.
The time for each gelatin composition to reach full hydration was measured with a digital stopwatch. Hydrated samples were weighed and reweighed to assure full hydration. Hydration was also determined by monitoring when the composition turned from opaque to translucent. The results of this evaluation are shown in Table 2. Where two values are given, duplicate runs were made.
Figure imgf000020_0001
Figure imgf000021_0001
The wet/dry ratio reported is the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material. All samples of cross-linked gelatin, treated or not, yielded very large and similar uptakes for water (wet/dry weight). Also, as evident above, the best wetting agents were deemed those that produced the most rapid hydration, e.g., Tween 20, Brij 35 and Brij 78. EXAMPLE 3
Demonstration of Improved Hydration Time for Cross-Linked Gelatins with Wetting Agent Coatings Containing Ethanol and Isopropanol Carrier Solvents
The purpose of this example is to demonstrate that the improved hydration time achieved for cross-linked gelatins coated with non-aqueous wetting agents as per Example 2 above were independent of the solvent used to coat the gelatin.
Specifically, gelatin composition 3 A was prepared in the same manner as gelatin composition 2A. The wetting agent coating solution comprises a selected wetting agent and a carrier solvent of either ethanol or isopropanol. Soak contact time of the foam in the wetting solution was about 10 seconds each.
After the coating layer has dried, the gelatin compositions were compressed and soaked in a 250 mL beaker containing 100 mL of RO water. The hydration times were measured as in Example 2. The specific wetting agents employed were as follows:
1. Tween 20 (polyoxyethylene (20) sorbitan monolaurate) (Aldrich Cat. # 27434-8)
2. Pluronic F-68 (poly(ethylene oxide)-co-(propylene oxide) block), (as a sample of a non-ionic wetting agent— average molecular weight of about 8400) (commercially available from
BASF Corp.)
3. Pluronic P-105 (poly(ethylene oxide)-co-(propylene oxide) polymer), (as a sample of a non- ionic wetting agent- average molecular weight of about 6500) (commercially available from BASF Corp.)
4. Pluronic- 10R5 (poly(ethylene oxide)-co-(propylene oxide) polymer), (as a sample of a non- ionic wetting agent- average molecular weight of about 4550) (commercially available from BASF Corp.). 5. Pluronic-F38 (poly(ethylene oxide)-co-(propylene oxide) block), (as a sample of a non-ionic wetting agent— average molecular weight of about 5000) (commercially available from BASF Corp.).
Hydration times for the compositions are set forth in Table 3 below.
Where multiple values are given, multiple runs were made.
Table 3 Hydration Times for Gelatin Compositions 3A
Figure imgf000023_0001
The average wet/dry ratio for the above samples was approximately 44 with a range of from 39-56 wherein this ratio is calculated by the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material.
The above data demonstrates that there is no appreciable difference in the hydration time of the coated cross-linked gelatin using different solvents to coat the gelatin.
However, the solvent employed should be non-aqueous to the extent that water irreversible damages the foam. Preferably, the non-aqueous solvent is ethanol and/or isopropanol since methanol causes some degradation of the foam properties and acetone exhibits a disagreeable odor.
EXAMPLE 4
Hydration Times for Cross-linked Gelatin Compositions with Wetting Agent Coating of Varying Concentrations
This example examines the effect of wetting agent concentration on hydration time used to coat the cross-linked gelatin composition. Specifically, cross-linked gelatin compositions with wetting agent coatings were prepared as in Example 2. The wetting agent coating solutions were prepared with concentrations of the selected wetting agents of 0.1, 1.0, 3.0 and 10.0% . The hydration times were measured on compressed samples, in the manner set forth in Example 2. All of the wetting agents and concentrations demonstrated rapid hydration times, although at the highest concentration of 10%, the hydration time was somewhat reduced. The results are set forth in Table 4 below. Where multiple values are given, multiple runs were made.
Table 4 Hydration Times for Cross-Linked Gelatin Compositions with Wetting Agent Coatings of Varying Concentrations
Figure imgf000024_0001
Figure imgf000025_0001
The wet/dry ratio reported is the wet weight over the dry weight which provides a ratio of the amount of water absorbed per unit weight of dry material.
The above data demonstrates that the concentration of wetting agent employed in the coating solution does not materially affect the hydration time of the coated cross-linked gelatin.
EXAMPLE 5
Hydration Times for Cross-linked Gelatin Compositions with Wetting Agent of Varying Concentrations Incorporated Therein
This example evaluates the effect of wetting agent concentration used during the formation of a gelatin foam composition on both the hydration time and the wet/dry ratio. This example differs from the previous example in that the wetting agent is added to the composition prior to foam formation as per Example 1 rather than coating a prior formed cross-linked gelatin foam with the wetting agent as per Examples 2-4. Specifically, cross-linked gelatin compositions with wetting agents incorporated therein were prepared as in Example 1 except that 0.02 weight percent of formalin was used and wherein the wetting agent was added to the gelatin composition prior to foam formation. The wetting agent coating solutions were prepared with concentrations set forth in Table 5.
The hydration times for these gelatin compositions were measured by manually compressing each cut sample and dropping it into a beaker containing 150 mL of tap water. Hydration was complete when the foam turned translucent and were measured on compressed samples, in the manner set forth in Example 2. Hydration time of a control, similar to Comparative Gelatin Example 2B, was also measured.
The hydration times are set forth in the Table 5 below.
Table 5
Figure imgf000026_0001
These results indicate that gelatin foam compositions with wetting agents did not achieve the same level of foam formation as compared to the control.
Upon drying, foam heights for these compositions were further reduced, with the lowest concentration of surfactant causing less height reduction. The compositions with the wetting agents incorporated therein also tended to be softer and more resilient, more fibrous and with larger irregular cells than the control compositions. Again, the lowest concentration of surfactant (0.1 %) gave foams closer to the control. All gelatin foams with wetting agent incorporated therein demonstrated very rapid and complete hydration. Hydration was complete within 2 - 3 seconds for the surfactant gelatin samples compared to about 8 minutes for the control. At the 0.1 % level, the presence of the surfactant was sufficient to dramatically improve hydration times. Unfortunately, water uptake was significantly diminished for all surfactant samples, except those with the lowest concentration of surfactant. Mechanical strength of all the samples (wet or dry) was excellent, and equal to that of the control.
Based on the above data, when the wetting agent is incorporated prior to cross-linked gelatin foam formation, very low concentrations of wetting agent are preferred. Moreover, the data indicates minimal impact of low concentrations of wetting agent on reduced hydration time indicating that such low concentrations advantageously provide for a composition closer to control in many properties but surprisingly have excellent hydration times as compared to control. Preferred wetting agents as demonstrated in this example utilizing the addition of wetting agent prior to foam formation should not prevent foam sponge formation of the cross-linked gelatin.
EXAMPLE 6
This example demonstrates that the incorporation of a wetting agent into a gelatin composition does not deleteriously effect the clotting ability of the gelatin composition as compared to control. A partial thromboplastin test (PTT) was employed. The PTT assay is a general screening assay for the detection of coagulation abnormalities in the intrinsic coagulation pathway. This is particularly important because, notwithstanding improved hydration time, a cross- linked gelatin composition having an adverse effect on blood clotting would be contra-indicated for use, e.g., as a hemostatic sponge. Specifically, in this example, fresh whole human blood was drawn at
AppTec Laboratory Services using vacutainer tubes containing sodium citrate. The citrated whole blood was spun down. The plasma was separated from the red blood cells, pooled into a polypropylene test tube, and stored on ice. This plasma was used as the exposure medium for testing. The comparison sample, test tube, reference material and controls were placed in polypropylene tubes and exposed to plasma (determined by the 1 mL/4cm2 exposure ratio) for 15 minutes at 37 + 1 °C in an agitating water bath at 60 RPM. The volume of 0.3 mL of plasma was used to saturate the test and comparison articles prior to exposure. At the end of the incubation period, the plasma was removed from the materials. The plasma samples were placed on ice and tested on the Cascade M4.
The results are set forth in Tables 6 and 7 below.
Table 6
Figure imgf000029_0001
Table 7
Figure imgf000030_0001
If coagulation does not occur within 300 seconds, the result is reported as "300 sec "). The above data demonstrates that the compositions of this invention exhibit substantially equivalent effects on clotting time as compared to control and, accordingly, it was concluded that these compositions are compatible for use as, e.g., hemostatic sponges.
EXAMPLE 7 This example evaluates the histopathologic results of a total of 2 arterial femoral puncture sites from one pig, using the compositions of this invention. The objective of this evaluation was to assess the acute and chronic outcome of femoral puncture sites following closure with the compositions of this invention delivered into the tissue tract adjacent to the vessel puncture using a cannula delivery tube. The puncture wound in the right femoral artery was sealed with cross-linked gelatin composition comprising 0.1 % Tween 20 obtained from solvent coating of the composition per Example 2 above. The puncture wound in the left femoral artery was sealed with cross-linked gelatin composition comprising 0.3% Tween 20 obtained from solvent coating of the composition per Example 2 above. Subsequently, approximately 2-4 weeks later, the animal was sacrificed, the arteries adjacent the femoral puncture site were excised and fixed in formalin.
Specifically, the formalin-fixed arterial explants were trimmed in the area of interest every 3 mm into 11 to 14 segments (sections 1 to 14). The sections' sequence was started at the proximal end of each explant. The sections were embedded in paraffin, sectioned at approximately 5 microns three times serially, and stained with Hematoxylin and Eosin (HE), Masson's Trichrome (MT), and Verhoeffs Van Gieson (VVG) stain, respectively. Histologic evaluation was performed and data were recorded.
A 1 to 5 grading scale was utilized, where 1 is minimal, 2 is mild, 3 is moderate, 4 is marked, and 5 is severe. Loss of endothelium was graded according to circumferential spread of the change. The change of endothelium loss spanned approximately up to 20% of the circumference in grade 1, 20-40% in grade 2, 40-60% in grade 3, 60-80% in grade 4 and more than 80% in grade 5. Necrosis of the media was graded according to depth extension. The change of media necrosis extended into approximately up to 20% of the media thickness in grade 1, 20-40% in grade 2, 40-60% in grade 3, 60-80% in grade 4 and more than 80% in grade 5.
1-Animal 3094G - Right Femoral Artery:
Gross Observations: The segment of artery was 52 mm long. There were no significant gross changes in the intact explant. Trimming revealed sub- occlusive thrombosis in most sections (1 through 8) and partial thrombosis in sections 9 and 10. The delivery tract could not be seen grossly.
Microscopic Observations: The puncture site was observed in sections 9 and 10 (24 and 27 mm from origin). There was transmural laceration with regeneration and fibrosis of the edges. From these lacerated sites and the corresponding intimal areas of more proximal sections a partially organized thrombus projected into the lumen and was nearly occluding the lumen. There was mineralization of the media in a sub-intimal position (sections 1, 2, 7, 8, 9), due to localized media pressure necrosis (dystrophic mineralization). Mineralization was also observed in the organizing thrombus. There was slight to mild partial loss of endothelium in the proximal sections (sections 1-7) that was considered to be the result of erosion associated with termination catheterization. In approximately the proximal 2/3 of the explant (sections 1-10) there was fibrosis of the media, most likely due to pressure necrosis at the time of treatment. The implant was not observed. There was mature connective tissue in the adventitia possibly corresponding to the treatment tract. These microscopic observations are consistent with arterial needle puncture and healing.
2-Animal 3094G - Left Femoral Artery:
Gross Observations: The segment of artery was 50 mm long. There were no significant gross changes in the intact explant.
Microscopic Observations: Transmural laceration (puncture site) was observed in section 8 (18-21 mm, recut 3) and was characterized by bifocal laceration across the vessel with proliferation of fibrous granulation tissue across the lumen dividing the pre-existing arterial wall into two symmetrically placed remnants. The residual lumen was confined to one of the arterial remnants. The lumen was constructed (moderate stensosis) by intimal fibrous proliferation at the puncture site. There was mineralization of the external elastic lamina adjacent to the laceration site. There was moderate fibrosis in the adventitia at the laceration site and in a separate area in the more distant adventitial tissue that most likely corresponds to the puncture tract. There was no residual implant material and there was no significant inflammatory response in the tract. There was minimal to mild loss of endothelium that was considered to be the result of erosion associated with termination catheterization.
The access tract produced by the catheter was found in the vascular wall in both samples as a localized fibrosis in the adventitia and focal transmural fibrosis. The left artery displayed bifocal transmural laceration and healing by fibrous connective tissue and media regeneration bridging across the lumen, indicating focal puncture through opposite sides of the vessel. There was no significant occlusive thrombosis in the left artery but focal moderate stenosis associated with intimal hyperplasia at the puncture site was present. The right artery there was sub-occlusive thrombosis that proceeded from the puncture site and extended proximally. There was evidence of pronounced architectural disruption and media necrosis due to mechanical trauma to the vessel wall at the puncture site, believed to be responsible for thrombosis. No residual foam test material was observed. These microscopic observations are consistent with arterial needle puncture and healing.
The above data demonstrates that the compositions of this invention are well tolerated in vivo.
EXAMPLE 8 This example evaluates the cytotoxicity of the compositions of this invention as compared to prior art compositions, i.e., in the absence of a wetting agent. In this example, samples were tested in the ISO agarose overlay cytotoxicity test — a test well known in the art for determining cytotoxicity potential. Specifically, samples were placed onto petri dishes, in triplicate, containing agarose the surface of which contains a monolayer of L-929 mouse fibroblast cells which are sensitive to cytotoxic agents. Subsequently, the samples were evaluated for reactivity and grade depending upon the amount of cellular damage or death directly beneath and/or surrounding the material. The scoring is based on the following:
0 = no zone under or around sample
1 = some malformed or degenerated cells under sample
2 = zone limited to area under sample 3 = zone extends 0.5 to 1.0 cm beyond sample
4 = zone extends greater than 1.0 cm
In this example, a score of 0-2 is deemed to be non- toxic; a score of 3 is deemed to be weakly or moderately toxic; and a score of 4 is strongly toxic. The results of this evaluation are summarized below in Table 8:
Table 8
Figure imgf000035_0001
The above results demonstrate that the compositions of this invention, as ested in this example, are non-cy to toxic.
From the foregoing description, various modifications and changes in the above described methods will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

Claims

WHAT IS CLAIMED IS:
1. A biocompatible, hemostatic, cross-linked gelatin composition comprising a cross-linked gelatin and a sufficient amount of wetting agent to permit uniform wetting of the gelatin in the presence of an aqueous solution.
2. The hemostatic, cross-linked gelatin composition of Claim 1, wherein the wetting agent is impregnated with the gelatin prior to foaming of the gelatin.
3. The hemostatic, cross-linked gelatin composition of Claim 2, wherein the wetting agent is mixed with the gelatin prior to foaming.
4. The hemostatic, cross-linked gelatin of Claim 1, wherein the wetting agent is coated over the surface of the gelatin.
5. A method for decreasing the hydration time of a hemostatic, cross- linked gelatin composition which method comprises, prior to hydration of said cross-linked gelatin composition, incorporating a biocompatible wetting agent with said cross-linked gelatin.
6. The method of Claim 5, wherein said incorporation is achieved by mixing the wetting agent with the gelatin prior to foaming.
7. The method of Claim 5, wherein said incorporation is achieved by impregnating the gelatin with the wetting agent prior to foaming.
8. The method of Claim 5, wherein said incorporation is achieved by coating the wetting agent over the surface of the gelatin.
9. The hemostatic, cross-linked gelatin composition of Claim 1, wherein the composition is bioadsorbable.
10. The hemostatic, cross-linked gelatin composition of Claim 1, further comprising one or more compositions selected from the group consisting of growth factors, thrombus enhancing agents, and antimicrobial agents.
11. The hemostatic, cross-linked gelatin composition of Claims 2 or 3, wherein the wetting agent comprises 0.1 to 10 weight percent of the gelatin.
12. The method of Claim 8, wherein the coating is achieved by applying to the surface of the gelatin by a solution consisting of a liquid solvent and the wetting agent, wherein the concentration of the wetting agent in the solution is from 1 to 20 percent of the solution.
13. The method of Claim 12, wherein the liquid solvent is evaporated from the surface of the gelatin.
14. The method of Claim 12, wherein the concentration of the wetting agent, after evaporation of the liquid solvent, is from 0.01 to 5 weight percent of the gelatin composition.
15. The biocompatible, hemostatic sponge of Claim 1, wherein the sponge is sterilized and packaged for use in surgical procedures.
16. A kit of parts for preparing a biocompatible, hemostatic, cross- linked gelatin composition comprising a syringe and a non-hydrated pledget, said pledget consisting of cross-linked gelatin and wetting agent.
PCT/US2002/003381 2001-03-12 2002-02-14 Cross-linked gelatin composition comprising a wetting agent WO2002072128A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02720915.4A EP1389125B1 (en) 2001-03-12 2002-02-14 Cross-linked gelatin composition comprising a wetting agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27542001P 2001-03-12 2001-03-12
US60/275,420 2001-03-12

Publications (1)

Publication Number Publication Date
WO2002072128A1 true WO2002072128A1 (en) 2002-09-19

Family

ID=23052214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003381 WO2002072128A1 (en) 2001-03-12 2002-02-14 Cross-linked gelatin composition comprising a wetting agent

Country Status (3)

Country Link
US (3) US8187625B2 (en)
EP (1) EP1389125B1 (en)
WO (1) WO2002072128A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631262A2 (en) * 2003-06-12 2006-03-08 Sub Q, Inc. Improved system and method for facilitating hemostatis with an absorbable sponge
US7109163B2 (en) 2004-01-30 2006-09-19 Ethicon, Inc. Hemostatic compositions and devices
AU2004264873B2 (en) * 2003-08-07 2009-07-23 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
WO2009109963A1 (en) * 2008-03-03 2009-09-11 Omrix Biopharmaceuticals Ltd. A gelatin sponge comprising an active ingredient, its preparation and use
US7833965B2 (en) 2003-08-07 2010-11-16 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
EP2265728A1 (en) * 2008-04-03 2010-12-29 Zymogenetics, Inc. Hemostatic microspheres
US7942897B2 (en) 2003-07-10 2011-05-17 Boston Scientific Scimed, Inc. System for closing an opening in a body cavity
US8119160B2 (en) 2004-06-29 2012-02-21 Ethicon, Inc. Hemostatic compositions and devices
EP2555804A1 (en) * 2010-04-07 2013-02-13 Baxter International Inc. Hemostatic sponge
US8398677B2 (en) 2002-12-20 2013-03-19 Boston Scientific Scimed, Inc. Closure device with textured surface
US8440225B2 (en) 2003-08-07 2013-05-14 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US8709038B2 (en) 2002-12-20 2014-04-29 Boston Scientific Scimed, Inc. Puncture hole sealing device
CN105561375A (en) * 2016-01-05 2016-05-11 山东省药学科学院 Dopamine crosslinked gelatin liquid absorbing hemostatic sponge and preparation method thereof
EP2575770B1 (en) 2010-06-01 2017-03-22 Baxter International Inc Process for making dry and stable hemostatic compositions
EP2575775B1 (en) 2010-06-01 2018-04-04 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10595837B2 (en) 2013-06-21 2020-03-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071300A (en) * 1995-09-15 2000-06-06 Sub-Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US6315753B1 (en) * 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20010045575A1 (en) * 1998-05-01 2001-11-29 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) * 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US8187625B2 (en) 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
WO2002087636A1 (en) * 2001-03-12 2002-11-07 Sub-Q, Inc. Methods for sterilizing cross-linked gelatin compositions
US7008440B2 (en) * 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US6863680B2 (en) * 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7025748B2 (en) * 2001-11-08 2006-04-11 Boston Scientific Scimed, Inc. Sheath based blood vessel puncture locator and depth indicator
US7037323B2 (en) * 2001-11-08 2006-05-02 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
WO2004053051A2 (en) * 2002-12-11 2004-06-24 Ferrosan A/S Gelatine-based materials as swabs
US7875043B1 (en) 2003-12-09 2011-01-25 Sub-Q, Inc. Cinching loop
ATE475434T1 (en) * 2004-01-30 2010-08-15 Ferrosan As HEMOSTATIC SPRAYS AND COMPOSITIONS
US8992454B2 (en) * 2004-06-09 2015-03-31 Bard Access Systems, Inc. Splitable tip catheter with bioresorbable adhesive
WO2006005340A1 (en) * 2004-07-09 2006-01-19 Ferrosan A/S Haemostatic composition comprising hyaluronic acid
CN102014973A (en) 2008-02-29 2011-04-13 弗罗桑医疗设备公司 Device for promotion of hemostasis and/or wound healing
DE102008020197A1 (en) 2008-04-15 2009-10-22 Gelita Ag Fast wettable, hydrocolloid-containing material, process for its preparation and its use
JP5779249B2 (en) * 2011-08-02 2015-09-16 大日精化工業株式会社 Anti-adhesion medical material and method for producing the same
US11679177B2 (en) 2017-08-08 2023-06-20 Baxter International Inc. Polymeric compositions, delivery devices, and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2465357A (en) * 1944-08-14 1949-03-29 Upjohn Co Therapeutic sponge and method of making
US2899362A (en) * 1959-08-11 Hemostatic sponges and method of
US5399361A (en) * 1992-05-01 1995-03-21 Amgen Inc. Collagen-containing sponges as drug delivery compositions for proteins
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581235A (en) * 1897-04-20 Island
US1578517A (en) * 1924-12-23 1926-03-30 George N Hein Valve piston and barrel construction for hypodermic syringes
US2086580A (en) 1935-06-24 1937-07-13 Myron C Shirley Applicator
US2370319A (en) * 1944-11-07 1945-02-27 Dohner & Lippincott Paper perforator
US2492458A (en) 1944-12-08 1949-12-27 Jr Edgar A Bering Fibrin foam
US2507244A (en) 1947-04-14 1950-05-09 Upjohn Co Surgical gelatin dusting powder and process for preparing same
CH264752A (en) 1947-06-03 1949-10-31 Hoffmann La Roche Process for the manufacture of carriers for pharmaceuticals.
US2597011A (en) * 1950-07-28 1952-05-20 Us Agriculture Preparation of starch sponge
US2680442A (en) * 1952-04-04 1954-06-08 Frank L Linzmayer Disposable suppository casing
US2814294A (en) 1953-04-17 1957-11-26 Becton Dickinson Co Unit for and method of inhibiting and controlling bleeding tendencies
US2874776A (en) * 1954-06-07 1959-02-24 Royal Mcbee Corp Punch and die mechanism
US2824092A (en) * 1955-01-04 1958-02-18 Robert E Thompson Process of preparation of a gelatincarboxymethyl cellulose complex
US2761446A (en) 1955-03-30 1956-09-04 Chemical Specialties Co Inc Implanter and cartridge
GB858477A (en) 1959-07-16 1961-01-11 Yat Chuen Yuen Improvements in or relating to drinking straws
US3157524A (en) 1960-10-25 1964-11-17 Ethicon Inc Preparation of collagen sponge
US3358689A (en) 1964-06-09 1967-12-19 Roehr Products Company Inc Integral lancet and package
US3325366A (en) * 1964-11-09 1967-06-13 Seymour M Blaug Biologically absorbable foam packing bandage and process therefor
US3411505A (en) 1965-12-15 1968-11-19 Paul D. Nobis Device for interrupting arterial flow
US3703174A (en) 1970-07-14 1972-11-21 Medidyne Corp Method and apparatus for catheter injection
US3724465A (en) * 1971-07-22 1973-04-03 Kimberly Clark Co Tampon coated with insertion aid and method for coating
US3736939A (en) * 1972-01-07 1973-06-05 Kendall & Co Balloon catheter with soluble tip
US3874388A (en) 1973-02-12 1975-04-01 Ochsner Med Found Alton Shunt defect closure system
US4000741A (en) * 1975-11-03 1977-01-04 The Kendall Company Syringe assembly
US4098728A (en) 1976-01-02 1978-07-04 Solomon Rosenblatt Medical surgical sponge and method of making same
SE7608618L (en) 1976-07-30 1978-02-01 Medline Ab CLOSURE OF CHANNELS
SU782814A1 (en) 1977-01-18 1980-11-30 За витель Prosthesis for closing defect in heart tissues
US4218155A (en) 1978-02-10 1980-08-19 Etablissements Armor, S.A. Stick for applying a liquid
US4588395A (en) * 1978-03-10 1986-05-13 Lemelson Jerome H Catheter and method
US4900303A (en) * 1978-03-10 1990-02-13 Lemelson Jerome H Dispensing catheter and method
US4238480A (en) 1978-05-19 1980-12-09 Sawyer Philip Nicholas Method for preparing an improved hemostatic agent and method of employing the same
US4404970A (en) 1978-05-19 1983-09-20 Sawyer Philip Nicholas Hemostatic article and methods for preparing and employing the same
US4224945A (en) 1978-08-30 1980-09-30 Jonathan Cohen Inflatable expansible surgical pressure dressing
US4219026A (en) 1978-09-15 1980-08-26 The Kendall Company Bladder hemostatic catheter
US4211323A (en) 1978-12-01 1980-07-08 California Medical Developments, Inc. Disposable diagnostic swab having a stored culture medium
US4323072A (en) 1980-01-18 1982-04-06 Shiley, Incorporated Cannula for a vein distention system
US4340066A (en) 1980-02-01 1982-07-20 Sherwood Medical Industries Inc. Medical device for collecting a body sample
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4390018A (en) * 1980-09-15 1983-06-28 Zukowski Henry J Method for preventing loss of spinal fluid after spinal tap
SU1088709A1 (en) 1981-02-10 1984-04-30 Институт Клинической И Экспериментальной Хирургии Method of treatment of stomach fistula
US4405314A (en) 1982-04-19 1983-09-20 Cook Incorporated Apparatus and method for catheterization permitting use of a smaller gage needle
NZ205033A (en) * 1982-08-12 1986-07-11 Univ Alabama Dispensing syringe with longitudinal slits in barrel
EP0135334A1 (en) * 1983-08-13 1985-03-27 Arthur Morris Fountain
US4573576A (en) * 1983-10-27 1986-03-04 Krol Thomas C Percutaneous gastrostomy kit
US4515637A (en) * 1983-11-16 1985-05-07 Seton Company Collagen-thrombin compositions
US4619913A (en) 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
US4619261A (en) 1984-08-09 1986-10-28 Frederico Guerriero Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system
US4587969A (en) * 1985-01-28 1986-05-13 Rolando Gillis Support assembly for a blood vessel or like organ
US4869143A (en) 1985-06-11 1989-09-26 Merrick Industries, Inc. Card file punch
US4708718A (en) 1985-07-02 1987-11-24 Target Therapeutics Hyperthermic treatment of tumors
US4644649A (en) * 1985-09-26 1987-02-24 Seaman Roy C Apparatus for trimming reeds of musical instruments
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
JPS62236560A (en) * 1986-04-09 1987-10-16 テルモ株式会社 Catheter for repairing blood vessel
US4699616A (en) 1986-06-13 1987-10-13 Hollister Incorporated Catheter retention device and method
US4852568A (en) 1987-02-17 1989-08-01 Kensey Nash Corporation Method and apparatus for sealing an opening in tissue of a living being
US4890612A (en) * 1987-02-17 1990-01-02 Kensey Nash Corporation Device for sealing percutaneous puncture in a vessel
US4744364A (en) * 1987-02-17 1988-05-17 Intravascular Surgical Instruments, Inc. Device for sealing percutaneous puncture in a vessel
US4839204A (en) * 1987-05-19 1989-06-13 Yazaki Kakoh Co., Ltd. Resin coated metal pipe having a plane surface for a lightweight structure
US4950234A (en) 1987-05-26 1990-08-21 Sumitomo Pharmaceuticals Company, Limited Device for administering solid preparations
US4829994A (en) * 1987-05-27 1989-05-16 Kurth Paul A Femoral compression device for post-catheterization hemostasis
US4836204A (en) * 1987-07-06 1989-06-06 Landymore Roderick W Method for effecting closure of a perforation in the septum of the heart
US4850960A (en) 1987-07-08 1989-07-25 Joseph Grayzel Diagonally tapered, bevelled tip introducing catheter and sheath and method for insertion
US4790819A (en) 1987-08-24 1988-12-13 American Cyanamid Company Fibrin clot delivery device and method
US5129889A (en) 1987-11-03 1992-07-14 Hahn John L Synthetic absorbable epidural catheter
US5195988A (en) * 1988-05-26 1993-03-23 Haaga John R Medical needle with removable sheath
US5254105A (en) 1988-05-26 1993-10-19 Haaga John R Sheath for wound closure caused by a medical tubular device
US4936835A (en) * 1988-05-26 1990-06-26 Haaga John R Medical needle with bioabsorbable tip
US5330445A (en) 1988-05-26 1994-07-19 Haaga John R Sheath for wound closure caused by a medical tubular device
US5080655A (en) * 1988-05-26 1992-01-14 Haaga John R Medical biopsy needle
US5053046A (en) 1988-08-22 1991-10-01 Woodrow W. Janese Dural sealing needle and method of use
US4920158A (en) * 1989-10-11 1990-04-24 Medipro Sciences Limited Hydrogel-forming wound dressing or skin coating material
US4929246A (en) * 1988-10-27 1990-05-29 C. R. Bard, Inc. Method for closing and sealing an artery after removing a catheter
JPH02182259A (en) * 1989-01-06 1990-07-16 Ube Ind Ltd Hemostatic sticking plaster
FR2641692A1 (en) 1989-01-17 1990-07-20 Nippon Zeon Co Plug for closing an opening for a medical application, and device for the closure plug making use thereof
US5007895A (en) * 1989-04-05 1991-04-16 Burnett George S Wound packing instrument
US5219899A (en) * 1989-04-22 1993-06-15 Degussa Aktiengesellschaft Pasty dental material which is an organopolysilane filler combined with a polymerizable bonding agent
US4973312A (en) 1989-05-26 1990-11-27 Andrew Daniel E Method and system for inserting spinal catheters
US5620461A (en) * 1989-05-29 1997-04-15 Muijs Van De Moer; Wouter M. Sealing device
DE3922406C1 (en) * 1989-07-07 1990-10-11 B. Braun Melsungen Ag, 3508 Melsungen, De
US5232453A (en) 1989-07-14 1993-08-03 E. R. Squibb & Sons, Inc. Catheter holder
GB8916781D0 (en) 1989-07-21 1989-09-06 Nycomed As Compositions
US5049138A (en) 1989-11-13 1991-09-17 Boston Scientific Corporation Catheter with dissolvable tip
US5061274A (en) 1989-12-04 1991-10-29 Kensey Nash Corporation Plug device for sealing openings and method of use
US5092873A (en) 1990-02-28 1992-03-03 Devices For Vascular Intervention, Inc. Balloon configuration for atherectomy catheter
US5021059A (en) * 1990-05-07 1991-06-04 Kensey Nash Corporation Plug device with pulley for sealing punctures in tissue and methods of use
US5595735A (en) * 1990-05-23 1997-01-21 Johnson & Johnson Medical, Inc. Hemostatic thrombin paste composition
US5299581A (en) * 1990-07-05 1994-04-05 Donnell John T Intravaginal device
US5192290A (en) * 1990-08-29 1993-03-09 Applied Medical Resources, Inc. Embolectomy catheter
US5391183A (en) * 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
EP0476178A1 (en) 1990-09-21 1992-03-25 Bioplex Medical B.V. Device for placing styptic material on perforated blood vessels
US5108421A (en) * 1990-10-01 1992-04-28 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5192300A (en) * 1990-10-01 1993-03-09 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US5167624A (en) 1990-11-09 1992-12-01 Catheter Research, Inc. Embolus delivery system and method
US5366480A (en) 1990-12-24 1994-11-22 American Cyanamid Company Synthetic elastomeric buttressing pledget
US5221259A (en) * 1990-12-27 1993-06-22 Novoste Corporation Wound treating device and method of using same
US5419765A (en) * 1990-12-27 1995-05-30 Novoste Corporation Wound treating device and method for treating wounds
US5458570A (en) 1991-01-22 1995-10-17 May, Jr.; James W. Absorbable catheter and method of using the same
US5310407A (en) * 1991-06-17 1994-05-10 Datascope Investment Corp. Laparoscopic hemostat delivery system and method for using said system
CA2078530A1 (en) 1991-09-23 1993-03-24 Jay Erlebacher Percutaneous arterial puncture seal device and insertion tool therefore
GB9123524D0 (en) 1991-11-06 1992-01-02 Tambrands Ltd Sanitary tampon
US5282827A (en) * 1991-11-08 1994-02-01 Kensey Nash Corporation Hemostatic puncture closure system and method of use
US5676689A (en) 1991-11-08 1997-10-14 Kensey Nash Corporation Hemostatic puncture closure system including vessel location device and method of use
US5163904A (en) 1991-11-12 1992-11-17 Merit Medical Systems, Inc. Syringe apparatus with attached pressure gauge
US5433725A (en) * 1991-12-13 1995-07-18 Unisurge, Inc. Hand-held surgical device and tools for use therewith, assembly and method
US6056768A (en) * 1992-01-07 2000-05-02 Cates; Christopher U. Blood vessel sealing system
CA2089999A1 (en) 1992-02-24 1993-08-25 H. Jonathan Tovey Resilient arm mesh deployer
US5220926A (en) * 1992-07-13 1993-06-22 Jones George T Finger mounted core biopsy guide
US5413571A (en) 1992-07-16 1995-05-09 Sherwood Medical Company Device for sealing hemostatic incisions
US5443481A (en) 1992-07-27 1995-08-22 Lee; Benjamin I. Methods and device for percutaneous sealing of arterial puncture sites
CZ281454B6 (en) * 1992-11-23 1996-10-16 Milan Mudr. Csc. Krajíček Aid for non-surgical closing of a hole in a vessel wall
US5334216A (en) 1992-12-10 1994-08-02 Howmedica Inc. Hemostatic plug
US5417699A (en) * 1992-12-10 1995-05-23 Perclose Incorporated Device and method for the percutaneous suturing of a vascular puncture site
BR9305045A (en) 1992-12-15 1994-07-26 Johnson & Johnson Laminate, composite, process to form a hydrogel laminate, bandage and method of covering a wound
SG52198A1 (en) 1993-01-25 1998-09-28 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
CA2095553A1 (en) 1993-02-12 1994-08-13 Kimberly-Clark Worldwide, Inc. Encapsulated catamenial tampon with and without an applicator
US5370656A (en) 1993-02-26 1994-12-06 Merocel Corporation Throat pack
US5320639A (en) * 1993-03-12 1994-06-14 Meadox Medicals, Inc. Vascular plug delivery system
US5322515A (en) * 1993-03-15 1994-06-21 Abbott Laboratories Luer adapter assembly for emergency syringe
US5342388A (en) 1993-03-25 1994-08-30 Sonia Toller Method and apparatus for sealing luminal tissue
US5388588A (en) 1993-05-04 1995-02-14 Nabai; Hossein Biopsy wound closure device and method
US5383896A (en) * 1993-05-25 1995-01-24 Gershony; Gary Vascular sealing device
AU7099994A (en) 1993-06-04 1995-01-03 Kensey Nash Corporation Hemostatic vessel puncture closure with filament lock
ATE141481T1 (en) * 1993-06-16 1996-09-15 White Spot Ag DEVICE FOR INTRODUCING FIBRIN GLUE INTO A STITCH CHANNEL
US5545175A (en) 1993-06-18 1996-08-13 Leonard Bloom Disposable quarded finger scalpel for inserting a line in a patent and lock off therefor
US5325857A (en) 1993-07-09 1994-07-05 Hossein Nabai Skin biopsy device and method
US5352211A (en) 1993-07-11 1994-10-04 Louisville Laboratories External stability device
US5486195A (en) * 1993-07-26 1996-01-23 Myers; Gene Method and apparatus for arteriotomy closure
DE4325969C1 (en) 1993-08-03 1994-09-08 Aesculap Ag By-pass instrument
US5462561A (en) 1993-08-05 1995-10-31 Voda; Jan K. Suture device
US5431639A (en) 1993-08-12 1995-07-11 Boston Scientific Corporation Treating wounds caused by medical procedures
US5653730A (en) 1993-09-28 1997-08-05 Hemodynamics, Inc. Surface opening adhesive sealer
US5383899A (en) 1993-09-28 1995-01-24 Hammerslag; Julius G. Method of using a surface opening adhesive sealer
ATE273035T1 (en) 1993-11-03 2004-08-15 Clarion Pharmaceuticals Inc HEMOSTATIC PLASTER
US5437292A (en) 1993-11-19 1995-08-01 Bioseal, Llc Method for sealing blood vessel puncture sites
US5507279A (en) 1993-11-30 1996-04-16 Fortune; John B. Retrograde endotracheal intubation kit
US5649547A (en) 1994-03-24 1997-07-22 Biopsys Medical, Inc. Methods and devices for automated biopsy and collection of soft tissue
US5526822A (en) 1994-03-24 1996-06-18 Biopsys Medical, Inc. Method and apparatus for automated biopsy and collection of soft tissue
US5385550A (en) * 1994-03-29 1995-01-31 Su; Chan-Ho Needle protective means for prevention against stab and virus infection
JPH09511666A (en) 1994-04-08 1997-11-25 アトリックス・ラボラトリーズ・インコーポレイテッド Ancillary polymer systems for use in medical devices
US5545178A (en) 1994-04-29 1996-08-13 Kensey Nash Corporation System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating
US5554029A (en) 1994-05-31 1996-09-10 Medical Laser Technology, Inc. Dental laser apparatus and method for ablating non-metallic dental material from a tooth
WO1995032669A1 (en) 1994-06-01 1995-12-07 Perclose, Inc. Apparatus and method for advancing surgical knots
WO1995032671A1 (en) 1994-06-01 1995-12-07 Perclose, Inc. Method and device for providing vascular hemostasis
US5522850A (en) 1994-06-23 1996-06-04 Incontrol, Inc. Defibrillation and method for cardioverting a heart and storing related activity data
US5931165A (en) 1994-09-06 1999-08-03 Fusion Medical Technologies, Inc. Films having improved characteristics and methods for their preparation and use
US5490736A (en) * 1994-09-08 1996-02-13 Habley Medical Technology Corporation Stylus applicator for a rehydrated multi-constituent medication
DE69534233T2 (en) 1994-09-16 2005-10-27 Ethicon Endo-Surgery, Inc., Cincinnati DEVICES FOR DETERMINING AND MARKING TISSUE
US5527332A (en) 1994-11-02 1996-06-18 Mectra Labs, Inc. Tissue cutter for surgery
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5624402A (en) * 1994-12-12 1997-04-29 Becton, Dickinson And Company Syringe tip cap
US5462194A (en) 1995-01-11 1995-10-31 Candea Inc. Self-venting straw tip
WO1996022123A1 (en) * 1995-01-18 1996-07-25 Medchem Products, Inc. Apparatus and method for applying a hemostatic agent onto a tissue
US5649959A (en) 1995-02-10 1997-07-22 Sherwood Medical Company Assembly for sealing a puncture in a vessel
US5571168A (en) 1995-04-05 1996-11-05 Scimed Lifesystems Inc Pull back stent delivery system
US6071300A (en) 1995-09-15 2000-06-06 Sub-Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US5645566A (en) 1995-09-15 1997-07-08 Sub Q Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US6162192A (en) * 1998-05-01 2000-12-19 Sub Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US5769086A (en) 1995-12-06 1998-06-23 Biopsys Medical, Inc. Control system and method for automated biopsy device
US5800389A (en) 1996-02-09 1998-09-01 Emx, Inc. Biopsy device
US5601207A (en) * 1996-03-13 1997-02-11 Paczonay; Joseph R. Bite valve having a plurality of slits
US5827218A (en) 1996-04-18 1998-10-27 Stryker Corporation Surgical suction pool tip
US5858008A (en) * 1997-04-22 1999-01-12 Becton, Dickinson And Company Cannula sealing shield assembly
US5902310A (en) * 1996-08-12 1999-05-11 Ethicon Endo-Surgery, Inc. Apparatus and method for marking tissue
US6706690B2 (en) * 1999-06-10 2004-03-16 Baxter Healthcare Corporation Hemoactive compositions and methods for their manufacture and use
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US6063061A (en) * 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5810806A (en) 1996-08-29 1998-09-22 Ethicon Endo-Surgery Methods and devices for collection of soft tissue
US5681279A (en) 1996-11-04 1997-10-28 Roper; David H. Pill dispensing syringe
US5782861A (en) 1996-12-23 1998-07-21 Sub Q Inc. Percutaneous hemostasis device
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US5868762A (en) * 1997-09-25 1999-02-09 Sub-Q, Inc. Percutaneous hemostatic suturing device and method
US6270464B1 (en) 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
US6033427A (en) * 1998-01-07 2000-03-07 Lee; Benjamin I. Method and device for percutaneous sealing of internal puncture sites
US20020076429A1 (en) * 1998-01-28 2002-06-20 John F. Wironen Bone paste subjected to irradiative and thermal treatment
US6161034A (en) 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US20010045575A1 (en) * 1998-05-01 2001-11-29 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US6610026B2 (en) 1998-05-01 2003-08-26 Sub-Q, Inc. Method of hydrating a sponge material for delivery to a body
US7625352B1 (en) 1998-05-01 2009-12-01 Sub-Q, Inc. Depth and puncture control for system for hemostasis of blood vessel
US6315753B1 (en) * 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6200328B1 (en) * 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
US6126675A (en) 1999-01-11 2000-10-03 Ethicon, Inc. Bioabsorbable device and method for sealing vascular punctures
AU2759500A (en) 1999-02-10 2000-08-29 Sub-Q Inc. Device and method for facilitating hemostasis of a biopsy tract
US6984219B2 (en) * 1999-09-23 2006-01-10 Mark Ashby Depth and puncture control for blood vessel hemostasis system
US7695492B1 (en) 1999-09-23 2010-04-13 Boston Scientific Scimed, Inc. Enhanced bleed back system
DE29920949U1 (en) 1999-11-29 2000-04-27 Bugge Mogens Suction tube for surgical purposes
US6547806B1 (en) * 2000-02-04 2003-04-15 Ni Ding Vascular sealing device and method of use
WO2001083174A1 (en) * 2000-04-28 2001-11-08 Sub-Q, Inc. Easy cutter
US6540735B1 (en) 2000-05-12 2003-04-01 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
WO2002005865A2 (en) 2000-07-14 2002-01-24 Sub-Q, Inc. Sheath-mounted arterial plug delivery device
US7201725B1 (en) 2000-09-25 2007-04-10 Sub-Q, Inc. Device and method for determining a depth of an incision
US6503222B2 (en) * 2000-09-28 2003-01-07 Pfizer Inc Oral dosage dispenser
US8187625B2 (en) 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
US7008440B2 (en) * 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US6863680B2 (en) * 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7029489B1 (en) 2001-05-18 2006-04-18 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site
US7037323B2 (en) 2001-11-08 2006-05-02 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7025748B2 (en) * 2001-11-08 2006-04-11 Boston Scientific Scimed, Inc. Sheath based blood vessel puncture locator and depth indicator
US7037322B1 (en) 2001-11-08 2006-05-02 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture with a staging tube
US20040102730A1 (en) 2002-10-22 2004-05-27 Davis Thomas P. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US8317821B1 (en) 2002-11-04 2012-11-27 Boston Scientific Scimed, Inc. Release mechanism
US7455680B1 (en) 2002-11-04 2008-11-25 Boston Scientific Scimed, Inc. Apparatus and method for inhibiting blood loss
US7955353B1 (en) 2002-11-04 2011-06-07 Sub-Q, Inc. Dissolvable closure device

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899362A (en) * 1959-08-11 Hemostatic sponges and method of
US2465357A (en) * 1944-08-14 1949-03-29 Upjohn Co Therapeutic sponge and method of making
US5399361A (en) * 1992-05-01 1995-03-21 Amgen Inc. Collagen-containing sponges as drug delivery compositions for proteins
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1389125A4 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709038B2 (en) 2002-12-20 2014-04-29 Boston Scientific Scimed, Inc. Puncture hole sealing device
US8398677B2 (en) 2002-12-20 2013-03-19 Boston Scientific Scimed, Inc. Closure device with textured surface
EP1631262A2 (en) * 2003-06-12 2006-03-08 Sub Q, Inc. Improved system and method for facilitating hemostatis with an absorbable sponge
JP2007501688A (en) * 2003-06-12 2007-02-01 ボストン サイエンティフィック リミテッド Improved system and method for promoting hemostasis using absorbent sponges
EP1631262A4 (en) * 2003-06-12 2010-05-05 Boston Scient Ltd An Irish Co Improved system and method for facilitating hemostatis with an absorbable sponge
JP4703568B2 (en) * 2003-06-12 2011-06-15 ボストン サイエンティフィック リミテッド Method for producing hemostatic material
US7942897B2 (en) 2003-07-10 2011-05-17 Boston Scientific Scimed, Inc. System for closing an opening in a body cavity
AU2009202172A8 (en) * 2003-08-07 2011-06-23 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
AU2004264873B2 (en) * 2003-08-07 2009-07-23 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US9005609B2 (en) 2003-08-07 2015-04-14 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US7833965B2 (en) 2003-08-07 2010-11-16 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
AU2009202172B2 (en) * 2003-08-07 2011-05-26 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US7718412B2 (en) 2003-08-07 2010-05-18 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US8551941B2 (en) 2003-08-07 2013-10-08 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
AU2009202172B8 (en) * 2003-08-07 2011-06-23 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US8440225B2 (en) 2003-08-07 2013-05-14 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US7109163B2 (en) 2004-01-30 2006-09-19 Ethicon, Inc. Hemostatic compositions and devices
US8119160B2 (en) 2004-06-29 2012-02-21 Ethicon, Inc. Hemostatic compositions and devices
WO2009109963A1 (en) * 2008-03-03 2009-09-11 Omrix Biopharmaceuticals Ltd. A gelatin sponge comprising an active ingredient, its preparation and use
US8475812B2 (en) 2008-03-03 2013-07-02 Omrix Biopharmaceuticals Ltd. Gelatin sponge comprising an active ingredient, its preparation and use
US9427490B2 (en) 2008-03-03 2016-08-30 Omrix Biopharmaceuticals Ltd. Gelatin sponge comprising an active ingredient, its preparation and use
US8981058B2 (en) 2008-03-03 2015-03-17 Omrix Biopharmaceuticals Ltd. Gelatin sponge comprising an active ingredient, its preparation and use
CN101970021A (en) * 2008-03-03 2011-02-09 奥姆里克斯生物药品有限公司 A gelatin sponge comprising an active ingredient, its preparation and use
EP2265728A4 (en) * 2008-04-03 2012-08-01 Zymogenetics Inc Hemostatic microspheres
US11246938B2 (en) 2008-04-03 2022-02-15 Baxter International Inc. Hemostatic microspheres
EP2265728A1 (en) * 2008-04-03 2010-12-29 Zymogenetics, Inc. Hemostatic microspheres
US9629798B2 (en) 2008-04-03 2017-04-25 Mallinckrodt Pharma Ip Trading D.A.C. Hemostatic microspheres
AU2011237901B2 (en) * 2010-04-07 2014-07-10 Baxter Healthcare S.A. Hemostatic sponge
US10441674B2 (en) 2010-04-07 2019-10-15 Baxter International Inc. Hemostatic sponge
US11478566B2 (en) 2010-04-07 2022-10-25 Baxter International Inc. Hemostatic sponge
EP2555804A1 (en) * 2010-04-07 2013-02-13 Baxter International Inc. Hemostatic sponge
EP2555804B1 (en) * 2010-04-07 2015-06-03 Baxter International Inc. Hemostatic sponge
US9375505B2 (en) 2010-04-07 2016-06-28 Baxter International Inc. Hemostatic sponge
EP2575775B1 (en) 2010-06-01 2018-04-04 Baxter International Inc. Process for making dry and stable hemostatic compositions
EP2575770B1 (en) 2010-06-01 2017-03-22 Baxter International Inc Process for making dry and stable hemostatic compositions
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US10799611B2 (en) 2012-06-12 2020-10-13 Ferrosan Medical Devices A/S Dry haemostatic composition
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10595837B2 (en) 2013-06-21 2020-03-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US11103616B2 (en) 2013-12-11 2021-08-31 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN105561375B (en) * 2016-01-05 2018-11-30 山东省药学科学院 A kind of gelatin liquid-absorbent hemostatic sponge and preparation method thereof of dopamine crosslinking
CN105561375A (en) * 2016-01-05 2016-05-11 山东省药学科学院 Dopamine crosslinked gelatin liquid absorbing hemostatic sponge and preparation method thereof
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Also Published As

Publication number Publication date
EP1389125A1 (en) 2004-02-18
EP1389125A4 (en) 2007-07-25
US20120232013A1 (en) 2012-09-13
US8187625B2 (en) 2012-05-29
EP1389125B1 (en) 2014-08-20
US8821918B2 (en) 2014-09-02
US8524270B2 (en) 2013-09-03
US20130324470A1 (en) 2013-12-05
US20030028140A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
US8821918B2 (en) Cross-linked gelatin composition comprising a wetting agent
US10322170B2 (en) Hemostatic compositions
JP5232347B2 (en) Blood active compositions and methods for their manufacture and use
US9821025B2 (en) Hemostatic compositions
US5595735A (en) Hemostatic thrombin paste composition
KR101811070B1 (en) Hemostatic sponge
JP3285887B2 (en) Process for producing a neutralized oxidized cellulose product and its use
EP1137446A1 (en) Collagen hemostatic foam
KR101735899B1 (en) Biodegradable non-woven material for medical purposes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002720915

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002720915

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP